JP2017510552A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510552A5
JP2017510552A5 JP2016550760A JP2016550760A JP2017510552A5 JP 2017510552 A5 JP2017510552 A5 JP 2017510552A5 JP 2016550760 A JP2016550760 A JP 2016550760A JP 2016550760 A JP2016550760 A JP 2016550760A JP 2017510552 A5 JP2017510552 A5 JP 2017510552A5
Authority
JP
Japan
Prior art keywords
modulator
fibrosis
composition
item
regulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016550760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510552A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/014939 external-priority patent/WO2015120350A2/en
Publication of JP2017510552A publication Critical patent/JP2017510552A/ja
Publication of JP2017510552A5 publication Critical patent/JP2017510552A5/ja
Pending legal-status Critical Current

Links

JP2016550760A 2014-02-07 2015-02-07 線維性疾患を治療するための方法 Pending JP2017510552A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461937272P 2014-02-07 2014-02-07
US61/937,272 2014-02-07
US201462010004P 2014-06-10 2014-06-10
US62/010,004 2014-06-10
US201462037497P 2014-08-14 2014-08-14
US62/037,497 2014-08-14
PCT/US2015/014939 WO2015120350A2 (en) 2014-02-07 2015-02-07 Compositions and methods for treating fibrotic disease

Publications (2)

Publication Number Publication Date
JP2017510552A JP2017510552A (ja) 2017-04-13
JP2017510552A5 true JP2017510552A5 (enExample) 2018-03-22

Family

ID=52684645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550760A Pending JP2017510552A (ja) 2014-02-07 2015-02-07 線維性疾患を治療するための方法

Country Status (7)

Country Link
US (2) US9993494B2 (enExample)
EP (1) EP3102703A2 (enExample)
JP (1) JP2017510552A (enExample)
CN (1) CN106102775A (enExample)
AU (1) AU2015213721B2 (enExample)
CA (1) CA2938592A1 (enExample)
WO (1) WO2015120350A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US11026945B2 (en) * 2016-04-29 2021-06-08 The Trustees Of The University Of Pennsylvania Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
US10894960B2 (en) 2016-08-30 2021-01-19 Children's Hospital Medical Center Compositions and methods for nucleic acid transfer
US11759437B2 (en) 2016-09-22 2023-09-19 The University Of Hong Kong Preventive and therapeutic approach for aberrant cell differentiation and ISR-associated diseases
WO2018149978A1 (en) * 2017-02-16 2018-08-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. ALTERNATIVE ACTIVATION OF MACROPHAGES (M2 CELLS) THROUGH THE POLYAMINE-eIF5a-HYPUSINE AXIS
US12411144B2 (en) 2017-03-22 2025-09-09 Children's Hospital Medical Center Compositions and methods for treatment of lung function
CN106983738B (zh) * 2017-04-13 2020-03-10 深圳市润佳通科技有限公司 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防皮肤疾病的药物中的应用
CA3063563A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Compositions and methods for an improved antitumor immune response
CN107260730B (zh) * 2017-05-31 2019-10-22 上海市东方医院 组蛋白去乙酰化酶hdac6的抑制剂在制备防治腹膜透析后腹膜纤维化的药物中的用途
WO2019022600A1 (en) 2017-07-24 2019-01-31 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47
WO2019022257A1 (ja) 2017-07-28 2019-01-31 杏林製薬株式会社 線維症治療剤
CN107326093B (zh) * 2017-09-04 2020-01-21 东南大学 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用
CN107916254B (zh) * 2017-11-29 2020-05-12 武汉大学 Homer1单克隆抗体及其应用
CN108192984B (zh) * 2018-02-13 2020-06-23 浙江大学 与湖羊肉质性状相关的分子标记及特异性引物对和应用
WO2019180664A1 (en) * 2018-03-21 2019-09-26 The University Of Hong Kong Method for preventing or modulating fibrosis and fibrotic response associated with the integrated stress response
BR112021026682A2 (pt) 2019-07-02 2022-03-15 Effector Therapeutics Inc Compostos e métodos para inibir eif4e
KR102100163B1 (ko) * 2019-09-24 2020-04-13 테고사이언스 (주) 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물
US12618855B2 (en) 2019-10-08 2026-05-05 Children's Hospital Medical Center Serum protein biomarker panel for idiopathic pulmonary fibrosis
CN111228464A (zh) * 2020-02-28 2020-06-05 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 广谱抗冠状病毒的多肽及其用途
CN113679841A (zh) * 2020-05-19 2021-11-23 上海市同济医院 一种磷脂酶d1(pld1)基因及其抑制剂在肝纤维化防治中的应用
US11304947B2 (en) 2020-05-22 2022-04-19 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with SARS-COV-2 infections
US20230201144A1 (en) * 2020-05-29 2023-06-29 Novomedix, Llc Biarylsulfonamides and pharmaceutical compositions thereof, and their use for treating fibrotic lung disease
EP4217378A4 (en) * 2020-10-08 2025-02-26 The Trustees Of Dartmouth College Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions
US20240066021A1 (en) * 2021-01-15 2024-02-29 Children's Hospital Medical Center Methods for optimizing cftr-modulator therapy
GB202109534D0 (en) * 2021-07-01 2021-08-18 Anglia Ruskin Univ Higher Education Corporation Treatment of scarring
KR20240041963A (ko) * 2021-07-22 2024-04-01 상하이 신비다 바이오테크놀로지 컴퍼니 리미티드 섬유성 질환을 완화 또는 치료하는 약학 조성물 또는 약제학적 키트 및 이의 용도
CA3240997A1 (en) * 2021-12-17 2023-06-22 Regeneron Pharmaceuticals, Inc. Treatment of lung conditions with integrin subunit alpha 1 (itga1) inhibitors
CN115558712B (zh) * 2022-09-22 2026-03-24 华中科技大学同济医学院附属协和医院 Fam177a1的新用途
CN116042624B (zh) * 2023-02-01 2026-07-24 南京医科大学 敲低或抑制环状RNA circ0030586的医药用途
CN117281906B (zh) * 2023-10-18 2026-06-26 浙江大学 Csrnp1抑制剂在制备治疗肝脏缺血再灌注损伤药物中的应用
AU2024370366A1 (en) * 2023-11-03 2026-06-18 Jumbo Drug Bank Co., Ltd. Use of pyrrolotriazine compound in preparation of drug for preventing and/or treating fibrosis or related disease thereof
CN117589999A (zh) * 2023-11-17 2024-02-23 深圳市人民医院 Pfkp作为慢性肾脏疾病治疗靶点的应用及其抑制剂
EP4714443A1 (en) * 2024-09-19 2026-03-25 Fundación Pública Galega Instituto de Investigación Sanitaria de Santiago de Compostela Heme-regulated inhibitor kinase activators for the treatment of neurological disorders
CN120789266A (zh) * 2025-09-10 2025-10-17 山东第一医科大学第一附属医院(山东省千佛山医院) Eif3a抑制剂在制备治疗肝纤维化药物中的应用
CN121243142A (zh) * 2025-12-01 2026-01-02 深圳大学 抑制eIF4A1蛋白表达的物质在制备抗肾纤维化的药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
EP1693059A1 (en) 2005-02-22 2006-08-23 Deutsches Krebsforschungszentrum Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases
JP4512828B2 (ja) * 2005-04-12 2010-07-28 国立大学法人 千葉大学 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット
WO2007027509A2 (en) * 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
GB0617117D0 (en) * 2006-08-31 2006-10-11 Renovo Ltd Method of diagnosis
US20090004668A1 (en) * 2007-06-22 2009-01-01 The Board Of Trustees Of The Leland Stanford Junior University Pre-miRNA loop-modulated target regulation
US7550300B1 (en) * 2007-11-29 2009-06-23 Capgen Sciences, Inc. Prediction of bare metal stent restenosis
AU2009319907B2 (en) 2008-11-03 2015-10-01 The Regents Of The University Of California Methods for detecting modification resistant nucleic acids
CN102300568A (zh) 2008-12-05 2011-12-28 赢泰医药科技发展有限公司 Hif-1蛋白积聚的抑制剂
US20100152531A1 (en) * 2008-12-11 2010-06-17 Paracor Medical, Inc. Implantable medical device for drug delivery and method of use
US20110319338A1 (en) * 2008-12-18 2011-12-29 The Board Of Regents Of The University Of Texas System Peptides that bind eukaryotic translation initiation factor 4e
EP2496944A2 (en) * 2009-11-05 2012-09-12 Novartis AG Biomarkers predictive of progression of fibrosis
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
WO2011140334A2 (en) 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
EP2576532B1 (en) 2010-06-07 2018-07-18 Novomedix, LLC Furanyl compounds and the use thereof
CA2803880C (en) 2010-06-28 2018-09-25 President And Fellows Of Harvard College Compounds for the inhibition of cellular proliferation
WO2014085633A1 (en) 2012-11-30 2014-06-05 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
WO2014124339A2 (en) 2013-02-07 2014-08-14 The Regents Of The University Of California Use of translational profiling to identify target molecules for therapeutic treatment
WO2014124412A2 (en) 2013-02-11 2014-08-14 President And Fellows Of Harvard College Methods and compounds for the inhibition of cellular proliferation

Similar Documents

Publication Publication Date Title
US10576098B2 (en) Compositions and methods for treating fibrotic disease
Sun et al. Cellular senescence: the sought or the unwanted?
Bonelli et al. Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells
Asghar et al. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
Sang et al. MicroRNA-133a improves the cardiac function and fibrosis through inhibiting Akt in heart failure rats
JP7367910B2 (ja) がんの処置
US20190136321A1 (en) Use of translational profiling to identify target molecules for therapeutic treatment
CN119235863A (zh) 用于免疫病况的治疗的mk2途径抑制剂的口服组合物
KR20160048196A (ko) 교모세포종의 치료를 위한 진단 방법 및 조성물
Li et al. Dexamethasone combined with berberine is an effective therapy for bleomycin-induced pulmonary fibrosis in rats
JP2018516244A5 (enExample)
Srikanthan et al. Creating a biomarker panel for early detection of chemotherapy related cardiac dysfunction in breast cancer patients
Cai et al. C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation
JOP20240120A1 (ar) مشتقات 4-فينيل-2-(1h-3،2،1-تريازول-4-يل) بيبيريدين-4-أول كمثبطات لـ apol1 وطرق استخدامها
Dey et al. CopA3 peptide inhibits MDM2-p53 complex stability in colorectal cancers and activates p53 mediated cell death machinery
Lemay et al. Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies
Zhang et al. IGF2BP1-HAX-1 positive feedback loop-mediated HAX-1 overexpression blocks autophagic flux and promotes chemoresistance in nasopharyngeal carcinoma: S. Zhang et al.
Russell et al. Inhibiting autophagy in renal cell cancer and the associated tumor endothelium
US20200360375A1 (en) Small molecule wnt inhibitor as treatment for dyslipidemia
JP2016088926A5 (enExample)
BR112014024230A8 (pt) Polipeptídeo, derivado do polipeptídeo, ácido nucleico, vetor, célula hospedeira, método de produção do polipeptídeo, composição farmacêutica, kit, método de inibição de atividade de notch, método de tratamento de uma doença, anticorpo isolado, método de o aumento da atividade de notch
Gadgeel MS05. 03 Notch Signalling
Ri et al. The KLF6 super-enhancer determines KLF6 sensitivity to BRD4 inhibitors in human hepatoma (HepG2) cells
White Transcriptional Regulators in Cancer: Exploring YAP/TAZ-Driven Signaling Mechanisms and Super Enhancer Elements
Santoni et al. Pre-treatment neutrophil to lymphocyte ratio as an independent prognostic factor in patients with treated with everolimus for metastatic renal cell carcinoma